he second-line treatment of gastric and gastroesophageal junction (GEJ) cancers has shifted considerably in the last few years, due in part to the addition of immunotherapy for select subgroups of patients.
https://www.onclive.com/conference-coverage/soss-gi-usc-2018/role-of-immunotherapy-may-expand-in-gastricgej-cancers
Role of Immunotherapy May Expand in Gastric/GEJ Cancers